» Articles » PMID: 30923781

Re-emerging Role of Macroscopic Appearance in Treatment Strategy for Gastric Cancer

Overview
Date 2019 Mar 30
PMID 30923781
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Pathological outcomes are definitely the most important prognostic factors in gastric cancer, but they can be obtained only after surgical resection. Use of preoperative adjuvant chemotherapy is becoming widespread for aggressive human cancer, so clinical factors such as macroscopic features are important as they are highly predictive for patient prognosis. In gastric cancer, the macroscopic type represents a distinct prognosis; Type 0 represents early gastric cancer with excellent prognosis, but, among advanced tumors, giant Type III and Type IV tumors have a dismal prognosis. Japan Clinical Oncology Group (JCOG) Stomach Cancer Study Group adopted macroscopic features as high-risk entities in clinical trials. It makes sense for risk classification to use macroscopic phenotypes because The Cancer Genome Atlas (TCGA) Network has lately subcategorized different histologies associated with specific macroscopic types by the molecular features of the whole genome. Dismal prognosis of Type IV gastric cancer is notorious, but similar prognosis was seen in giant Type III gastric cancer defined as 8 cm or beyond, both of which are unique for their propensity of peritoneal dissemination. In this review, clinical relevance including prognosis of such macroscopic high-risk features will be separately debated in the context of precision medicine and updated prognostic outcomes will be presented under the present standard therapy of curative surgery followed by postoperative S-1 chemotherapy. Moreover, promising emerging novel therapeutic strategies including trimodal potent regimens or intraperitoneal chemotherapy will be described for such aggressive gastric cancer.

Citing Articles

Oncological similarities between large type 3 and type 4 tumors in patients with resectable gastric cancer: a propensity score-matched analysis of a multi-institutional dataset.

Nakanishi K, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K Gastric Cancer. 2024; 27(6):1331-1341.

PMID: 39174850 PMC: 11513756. DOI: 10.1007/s10120-024-01546-x.


Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy.

Ichikawa H, Aizawa M, Kano Y, Hanyu T, Muneoka Y, Hiroi S Gastric Cancer. 2024; 27(6):1273-1286.

PMID: 39110344 DOI: 10.1007/s10120-024-01542-1.


Nomogram Based on Preoperative Fibrinogen and Systemic Immune-Inflammation Index Predicting Recurrence and Prognosis of Patients with Borrmann Type III Advanced Gastric Cancer.

Wang H, Yin X, Ma K, Wang Y, Fang T, Zhang Y J Inflamm Res. 2023; 16:1059-1075.

PMID: 36936348 PMC: 10019083. DOI: 10.2147/JIR.S404585.


The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer.

Javed A, Yarmohammadi M, Korkmaz K, Rubio-Tomas T Int J Mol Sci. 2023; 24(3).

PMID: 36769170 PMC: 9917736. DOI: 10.3390/ijms24032848.


Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer.

Wang Y, Fang T, Wang Y, Yin X, Zhang L, Zhang X BMC Cancer. 2022; 22(1):635.

PMID: 35681154 PMC: 9178847. DOI: 10.1186/s12885-022-09594-1.


References
1.
Choi Y, Yeo S, Kim Y, Lee J, Kim S, Park D . Comparison of innate immunity mediators in peritoneal fluid and spleen between young and aged rats. Aging Clin Exp Res. 2015; 28(4):775-9. DOI: 10.1007/s40520-015-0468-3. View

2.
Liu J, Kim M, Nagpal J, Yamashita K, Poeta L, Chang X . Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int J Cancer. 2007; 121(9):1994-2000. DOI: 10.1002/ijc.22934. View

3.
Tsujiura M, Hiki N, Ohashi M, Nunobe S, Kumagai K, Ida S . Excellent Long-Term Prognosis and Favorable Postoperative Nutritional Status After Laparoscopic Pylorus-Preserving Gastrectomy. Ann Surg Oncol. 2017; 24(8):2233-2240. DOI: 10.1245/s10434-017-5828-0. View

4.
Msika S, Benhamiche A, Jouve J, Rat P, Faivre J . Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer. 2000; 36(3):390-6. DOI: 10.1016/s0959-8049(99)00308-1. View

5.
Kitagawa Y, Fujii H, Mukai M, Kubota T, Otani Y, Kitajima M . Radio-guided sentinel node detection for gastric cancer. Br J Surg. 2002; 89(5):604-8. DOI: 10.1046/j.1365-2168.2002.02065.x. View